Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Neoplasm Metastasis 1Glioblastoma 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 61Radiotherapy 25Bevacizumab 21Magnetic Resonance Spectroscopy 20Irinotecan 18Filgrastim 15Carboplatin 15Carmustine 11Surgical Procedures, Operative 10Etoposide 9antineoplaston AS 2-1 8antineoplaston A10 8Specimen Handling 8sargramostim 7Radiation 7Peripheral Blood Stem Cell Transplantation 7Everolimus 7Biopsy 7Vincristine 6Radiotherapy, Intensity-Modulated 6Procarbazine 6O(6)-benzylguanine 6Erlotinib Hydrochloride 6Topotecan 5Melphalan 5Magnetic Resonance Imaging 5Lomustine 5Genetic Therapy 5Cyclophosphamide 5Aminolevulinic Acid 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Astrocytoma × etirinotecan pegol × Clear all
NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡